39 results on '"Rima Hajjo"'
Search Results
2. Identifying a causal link between prolactin signaling pathways and COVID-19 vaccine-induced menstrual changes
- Author
-
Rima Hajjo, Ensaf Momani, Dima A. Sabbah, Nancy Baker, and Alexander Tropsha
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract COVID-19 vaccines have been instrumental tools in the fight against SARS-CoV-2 helping to reduce disease severity and mortality. At the same time, just like any other therapeutic, COVID-19 vaccines were associated with adverse events. Women have reported menstrual cycle irregularity after receiving COVID-19 vaccines, and this led to renewed fears concerning COVID-19 vaccines and their effects on fertility. Herein we devised an informatics workflow to explore the causal drivers of menstrual cycle irregularity in response to vaccination with mRNA COVID-19 vaccine BNT162b2. Our methods relied on gene expression analysis in response to vaccination, followed by network biology analysis to derive testable hypotheses regarding the causal links between BNT162b2 and menstrual cycle irregularity. Five high-confidence transcription factors were identified as causal drivers of BNT162b2-induced menstrual irregularity, namely: IRF1, STAT1, RelA (p65 NF-kB subunit), STAT2 and IRF3. Furthermore, some biomarkers of menstrual irregularity, including TNF, IL6R, IL6ST, LIF, BIRC3, FGF2, ARHGDIB, RPS3, RHOU, MIF, were identified as topological genes and predicted as causal drivers of menstrual irregularity. Our network-based mechanism reconstruction results indicated that BNT162b2 exerted biological effects similar to those resulting from prolactin signaling. However, these effects were short-lived and didn’t raise concerns about long-term infertility issues. This approach can be applied to interrogate the functional links between drugs/vaccines and other side effects.
- Published
- 2023
- Full Text
- View/download PDF
3. A cross-sectional study confirms temporary post-COVID-19 vaccine menstrual irregularity and the associated physiological changes among vaccinated women in Jordan
- Author
-
Ensaf Y. Almomani, Rima Hajjo, Ahmad Qablan, Dima A. Sabbah, and Abass Al-Momany
- Subjects
COVID-19 vaccine ,adverse events ,menstrual cycle irregularity ,vaccinated women ,Jordan ,Medicine (General) ,R5-920 - Abstract
BackgroundCOVID-19 vaccines continue to save people’s lives around the world; however, some vaccine adverse events have been a major concern which slowed down vaccination campaigns. Anecdotal evidence pointed to the vaccine effect on menstruation but evidence from the adverse event reporting systems and the biomedical literature was lacking. This study aimed to investigate the physiological changes in women during menstruation amid the COVID-19 vaccination.MethodsA cross-sectional online survey was distributed to COVID-19 vaccinated women from Nov 2021 to Jan 2022. The results were analyzed using the SPSS software.ResultsAmong the 564 vaccinated women, 52% experienced significant menstrual irregularities post-vaccination compared to before regardless of the vaccine type. The kind of menstrual irregularity varied among the vaccinated women, for example, 33% had earlier menstruation, while 35% reported delayed menstruation. About 31% experienced heavier menstruation, whereas 24% had lighter menstrual flow. About 29% had menstruation last longer, but 13% had it shorter than usual. Noteworthy, the menstrual irregularities were more frequent after the second vaccine shot, and they disappeared within 3 months on average. Interestingly, 24% of the vaccinated women reported these irregularities to their gynecologist.ConclusionThe COVID-19 vaccine may cause physiological disturbances during menstruation. Luckily, these irregularities were short-termed and should not be a reason for vaccine hesitancy in women. Further studies are encouraged to unravel the COVID-19 vaccine adverse effect on women’s health.
- Published
- 2023
- Full Text
- View/download PDF
4. Exploring the effect of estrogen on Candida albicans hyphal cell wall glycans and ergosterol synthesis
- Author
-
Mohammad Tahseen AL Bataineh, Stefano Cacciatore, Mohammad Harb Semreen, Nihar Ranjan Dash, Nelson C. Soares, Xiaolong Zhu, Muath Khairi Mousa, Jasmin Shafarin Abdul Salam, Luiz F. Zerbini, Rima Hajjo, and Mawieh Hamad
- Subjects
Candida albicans ,estrogen ,ergosterol ,turanose ,vulvovaginal candidiasis (VC) ,Microbiology ,QR1-502 - Abstract
Increased levels of 17-β estradiol (E2) due to pregnancy in young women or to hormonal replacement therapy in postmenopausal women have long been associated with an increased risk of yeast infections. Nevertheless, the effect underlying the role of E2 in Candida albicans infections is not well understood. To address this issue, functional, transcriptomic, and metabolomic analyses were performed on C. albicans cells subjected to temperature and serum induction in the presence or absence of E2. Increased filament formation was observed in E2 treated cells. Surprisingly, cells treated with a combination of E2 and serum showed decreased filament formation. Furthermore, the transcriptomic analysis revealed that serum and E2 treatment is associated with downregulated expression of genes involved in filamentation, including HWP1, ECE1, IHD1, MEP1, SOD5, and ALS3, in comparison with cells treated with serum or estrogen alone. Moreover, glucose transporter genes HGT20 and GCV2 were downregulated in cells receiving both serum and E2. Functional pathway enrichment analysis of the differentially expressed genes (DEGs) suggested major involvement of E2 signaling in several metabolic pathways and the biosynthesis of secondary metabolites. The metabolomic analysis determined differential secretion of 36 metabolites based on the different treatments’ conditions, including structural carbohydrates and fatty acids important for hyphal cell wall formation such as arabinonic acid, organicsugar acids, oleic acid, octadecanoic acid, 2-keto-D-gluconic acid, palmitic acid, and steriacstearic acid with an intriguing negative correlation between D-turanose and ergosterol under E2 treatment. In conclusion, these findings suggest that E2 signaling impacts the expression of several genes and the secretion of several metabolites that help regulate C. albicans morphogenesis and virulence.
- Published
- 2022
- Full Text
- View/download PDF
5. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19
- Author
-
Rima Hajjo, Dima A. Sabbah, and Sanaa K. Bardaweel
- Subjects
Chemistry ,QD1-999 - Published
- 2020
- Full Text
- View/download PDF
6. Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases
- Author
-
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara, Reham Kharmah, and Sanaa Bardaweel
- Subjects
drug discovery intelligence ,drug repositioning ,host-targeted antivirals immune response pathways ,kinases ,signal transduction ,Microbiology ,QR1-502 - Abstract
Despite the great technological and medical advances in fighting viral diseases, new therapies for most of them are still lacking, and existing antivirals suffer from major limitations regarding drug resistance and a limited spectrum of activity. In fact, most approved antivirals are directly acting antiviral (DAA) drugs, which interfere with viral proteins and confer great selectivity towards their viral targets but suffer from resistance and limited spectrum. Nowadays, host-targeted antivirals (HTAs) are on the rise, in the drug discovery and development pipelines, in academia and in the pharmaceutical industry. These drugs target host proteins involved in the virus life cycle and are considered promising alternatives to DAAs due to their broader spectrum and lower potential for resistance. Herein, we discuss an important class of HTAs that modulate signal transduction pathways by targeting host kinases. Kinases are considered key enzymes that control virus-host interactions. We also provide a synopsis of the antiviral drug discovery and development pipeline detailing antiviral kinase targets, drug types, therapeutic classes for repurposed drugs, and top developing organizations. Furthermore, we detail the drug design and repurposing considerations, as well as the limitations and challenges, for kinase-targeted antivirals, including the choice of the binding sites, physicochemical properties, and drug combinations.
- Published
- 2023
- Full Text
- View/download PDF
7. A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics
- Author
-
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara, and Abdel Qader Al Bawab
- Subjects
Alzheimer’s disease (AD) ,diagnostic biomarkers ,drug prioritization ,epigenetics ,network biology ,multi-target drug ligands (MTDLs) ,Medicine (General) ,R5-920 - Abstract
Alzheimer’s disease (AD) is a polygenic multifactorial neurodegenerative disease that, after decades of research and development, is still without a cure. There are some symptomatic treatments to manage the psychological symptoms but none of these drugs can halt disease progression. Additionally, over the last few years, many anti-AD drugs failed in late stages of clinical trials and many hypotheses surfaced to explain these failures, including the lack of clear understanding of disease pathways and processes. Recently, different epigenetic factors have been implicated in AD pathogenesis; thus, they could serve as promising AD diagnostic biomarkers. Additionally, network biology approaches have been suggested as effective tools to study AD on the systems level and discover multi-target-directed ligands as novel treatments for AD. Herein, we provide a comprehensive review on Alzheimer’s disease pathophysiology to provide a better understanding of disease pathogenesis hypotheses and decipher the role of genetic and epigenetic factors in disease development and progression. We also provide an overview of disease biomarkers and drug targets and suggest network biology approaches as new tools for identifying novel biomarkers and drugs. We also posit that the application of machine learning and artificial intelligence to mining Alzheimer’s disease multi-omics data will facilitate drug and biomarker discovery efforts and lead to effective individualized anti-Alzheimer treatments.
- Published
- 2022
- Full Text
- View/download PDF
8. Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers
- Author
-
Rima Hajjo, Dima A. Sabbah, and Abdel Qader Al Bawab
- Subjects
biomarkers ,diagnostic biomarkers ,metagenomics ,microbial metabolites ,microbiome ,microbiome biomarkers ,Medicine (General) ,R5-920 - Abstract
The human microbiome encodes more than three million genes, outnumbering human genes by more than 100 times, while microbial cells in the human microbiota outnumber human cells by 10 times. Thus, the human microbiota and related microbiome constitute a vast source for identifying disease biomarkers and therapeutic drug targets. Herein, we review the evidence backing the exploitation of the human microbiome for identifying diagnostic biomarkers for human disease. We describe the importance of the human microbiome in health and disease and detail the use of the human microbiome and microbiota metabolites as potential diagnostic biomarkers for multiple diseases, including cancer, as well as inflammatory, neurological, and metabolic diseases. Thus, the human microbiota has enormous potential to pave the road for a new era in biomarker research for diagnostic and therapeutic purposes. The scientific community needs to collaborate to overcome current challenges in microbiome research concerning the lack of standardization of research methods and the lack of understanding of causal relationships between microbiota and human disease.
- Published
- 2022
- Full Text
- View/download PDF
9. Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects
- Author
-
Rima Hajjo, Dima A. Sabbah, and Alexander Tropsha
- Subjects
COVID-19 ,mRNA vaccine ,informatics workflow ,SARS-CoV-2 ,systems biology ,vaccine adverse events ,Medicine - Abstract
COVID-19 vaccines have been instrumental tools in reducing the impact of SARS-CoV-2 infections around the world by preventing 80% to 90% of hospitalizations and deaths from reinfection, in addition to preventing 40% to 65% of symptomatic illnesses. However, the simultaneous large-scale vaccination of the global population will indubitably unveil heterogeneity in immune responses as well as in the propensity to developing post-vaccine adverse events, especially in vulnerable individuals. Herein, we applied a systems biology workflow, integrating vaccine transcriptional signatures with chemogenomics, to study the pharmacological effects of mRNA vaccines. First, we derived transcriptional signatures and predicted their biological effects using pathway enrichment and network approaches. Second, we queried the Connectivity Map (CMap) to prioritize adverse events hypotheses. Finally, we accepted higher-confidence hypotheses that have been predicted by independent approaches. Our results reveal that the mRNA-based BNT162b2 vaccine affects immune response pathways related to interferon and cytokine signaling, which should lead to vaccine success, but may also result in some adverse events. Our results emphasize the effects of BNT162b2 on calcium homeostasis, which could be contributing to some frequently encountered adverse events related to mRNA vaccines. Notably, cardiac side effects were signaled in the CMap query results. In summary, our approach has identified mechanisms underlying both the expected protective effects of vaccination as well as possible post-vaccine adverse effects. Our study illustrates the power of systems biology approaches in improving our understanding of the comprehensive biological response to vaccination against COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
10. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients
- Author
-
Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, and Alexander Tropsha
- Subjects
COVID-19 ,myocarditis ,pericarditis ,SARS-CoV-2 ,systems biology ,vaccine ,Medicine - Abstract
Myocarditis and pericarditis have been linked recently to COVID-19 vaccines without exploring the underlying mechanisms, or compared to cardiac adverse events post-non-COVID-19 vaccines. We introduce an informatics approach to study post-vaccine adverse events on the systems biology level to aid the prioritization of effective preventive measures and mechanism-based pharmacotherapy by integrating the analysis of adverse event reports from the Vaccine Adverse Event Reporting System (VAERS) with systems biology methods. Our results indicated that post-vaccine myocarditis and pericarditis were associated most frequently with mRNA COVID-19 vaccines followed by live or live-attenuated non-COVID-19 vaccines such as smallpox and anthrax vaccines. The frequencies of cardiac adverse events were affected by vaccine, vaccine type, vaccine dose, sex, and age of the vaccinated individuals. Systems biology results suggested a central role of interferon-gamma (INF-gamma) in the biological processes leading to cardiac adverse events, by impacting MAPK and JAK-STAT signaling pathways. We suggest that increasing the time interval between vaccine doses minimizes the risks of developing inflammatory adverse reactions. We also propose glucocorticoids as preferred treatments based on system biology evidence. Our informatics workflow provides an invaluable tool to study post-vaccine adverse events on the systems biology level to suggest effective mechanism-based pharmacotherapy and/or suitable preventive measures.
- Published
- 2021
- Full Text
- View/download PDF
11. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML)
- Author
-
Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, and Alexander Tropsha
- Subjects
biomarkers ,imaging ,machine learning ,MRI ,oncology ,Medicine (General) ,R5-920 - Abstract
The identification of reliable and non-invasive oncology biomarkers remains a main priority in healthcare. There are only a few biomarkers that have been approved as diagnostic for cancer. The most frequently used cancer biomarkers are derived from either biological materials or imaging data. Most cancer biomarkers suffer from a lack of high specificity. However, the latest advancements in machine learning (ML) and artificial intelligence (AI) have enabled the identification of highly predictive, disease-specific biomarkers. Such biomarkers can be used to diagnose cancer patients, to predict cancer prognosis, or even to predict treatment efficacy. Herein, we provide a summary of the current status of developing and applying Magnetic resonance imaging (MRI) biomarkers in cancer care. We focus on all aspects of MRI biomarkers, starting from MRI data collection, preprocessing and machine learning methods, and ending with summarizing the types of existing biomarkers and their clinical applications in different cancer types.
- Published
- 2021
- Full Text
- View/download PDF
12. N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents
- Author
-
Dima A. Sabbah, Rawan A. Haroon, Sanaa K. Bardaweel, Rima Hajjo, and Kamal Sweidan
- Subjects
anticancer ,colon cancer ,PI3Kα ,AKT ,docking ,quinolone-3-carboxamide ,Organic chemistry ,QD241-441 - Abstract
Cancer is a multifactorial disease and the second leading cause of death worldwide. Diverse factors induce carcinogenesis, such as diet, smoking, radiation, and genetic defects. The phosphatidylinositol 3-kinase (PI3Kα) has emerged as an attractive target for anticancer drug design. Eighteen derivatives of N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamide were synthesized and characterized using FT-IR, NMR (1H and 13C), and high-resolution mass spectra (HRMS). The series exhibited distinct antiproliferative activity (IC50 µM) against human epithelial colorectal adenocarcinoma (Caco-2) and colon carcinoma (HCT-116) cell lines, respectively: compounds 16 (37.4, 8.9 µM), 18 (50.9, 3.3 µM), 19 (17.0, 5.3 µM), and 21 (18.9, 4.9 µM). The induced-fit docking (IFD) studies against PI3Kαs showed that the derivatives occupy the PI3Kα binding site and engage with key binding residues.
- Published
- 2020
- Full Text
- View/download PDF
13. Molecular Modeling, Synthesis and Biological Evaluation of N-Phenyl-4-Hydroxy-6-Methyl-2-Quinolone-3-CarboxAmides as Anticancer Agents
- Author
-
Dima A. Sabbah, Shaima’ E. Hasan, Reema Abu Khalaf, Sanaa K. Bardaweel, Rima Hajjo, Khalid M. Alqaisi, Kamal A. Sweidan, and Aya M. Al-Zuheiri
- Subjects
anticancer ,colon cancer ,PI3Kα ,AKT ,docking ,quinolone-3-carboxamide ,Organic chemistry ,QD241-441 - Abstract
The emergence of phosphatidylinositol 3-kinase (PI3Kα) in cancer development has accentuated its significance as a potential target for anticancer drug design. Twenty one derivatives of N-phenyl-4-hydroxy-6-methyl-2-quinolone-3-carboxamide were synthesized and characterized using NMR (1H and 13C) and HRMS. The derivatives displayed inhibitory activity against human epithelial colorectal adenocarcinoma (Caco-2) and human colon cancer (HCT-116) cell lines: compounds 8 (IC50 Caco-2 = 98 µM, IC50 HCT-116 = 337 µM) and 16 (IC50 Caco-2 = 13 µM, IC50 HCT-116 = 240.2 µM). Results showed that compound 16 significantly affected the gene encoding AKT, BAD, and PI3K. The induced-fit docking (IFD) studies against PI3Kα demonstrated that the scaffold accommodates the kinase domains and forms H-bonds with significant binding residues.
- Published
- 2020
- Full Text
- View/download PDF
14. Network biology of lapatinib resistance in different types of HER2-positive breast cancers informs the prioritization of the combination anticancer treatments as anti-resistance interventions [version 1; peer review: awaiting peer review]
- Author
-
Bayan Alkhawaja, Anas Khaleel, Wael Abu Dayyih, Mohammed F. Hamad, Rima Hajjo, and Mohammad Hailat
- Subjects
Research Article ,Articles ,Lapatinib resistance ,oncology ,anti-cancer agents ,HER2-amplified cancer ,Compensatory pathways ,SKBR3 cell line ,BT-474 cell line ,breast cancer. - Abstract
Background: With widespread therapeutic advancement, targeted anticancer therapeutics are taking over traditional treatment protocols. Nevertheless, the resistance to targeted therapeutics has halted the enthusiastic treatment response. An example of targeted therapy is Lapatinib. Lapatinib is a tyrosine kinase inhibitor used in HER2-positive breast cancer. It is widely used in HER2-positive metastatic breast cancer in combination with other drugs. Methods: This study's main objective was to provide a plausible mechanistic insight into lapatinib’s resistance in two HER2 positive breast cancer cell lines, SKBR3 and BT-474. We performed gene set analysis to identify the differentially expressed genes (DEG) in response to treatment with lapatinib from the gene expression profiles obtained from GSE38376 and GSE16179. The DEG was then analyzed by Ingenuity Pathway Analysis (IPA). Results: The IPA analysis showed that the increased expression of Hypoxia-inducible factor-1 alpha (HIF-1α) and Wnt/β-catenin and their related networks were associated with resistance and poor prognosis in SKBR3 and BT-474 cell lines, respectively. Although both cell lines are categorized as HER2 positive cell lines and in some reports were used interchangeably, in our hands, the two cell lines exhibited different biological pathways underlying resistance to lapatinib. In addition, among the other top canonical pathways, TNF was identified as the top upstream regulator in SKBR3 cell lines, whereas the Microphthalmia-associated transcription factor (MITF) was predicted as a top regulator in BT-474 cell lines. Conclusions: This study highlights the relevance of HIF-1α and Wnt/β-catenin compensatory networks in resistance toward lapatinib. Our findings outline the activation of angiogenesis and invasion processes in resistant cells with differential underlining gene networks in two different HER2 positive cell lines. The two cell lines reflect two different types of breast cancer, and hence the treatment strategy to avoid resistance should be planned differently.
- Published
- 2023
- Full Text
- View/download PDF
15. Compositional changes in human gut microbiota reveal a putative role of intestinal mycobiota in metabolic and biological decline during aging
- Author
-
Rima Hajjo, Nihar Ranjan Dash, Mohammad Tahseen Al Bataineh, Bayan Hassan Banimfreg, and Ayman Alzaatreh
- Subjects
Mycobiota ,Nutrition and Dietetics ,Human gut ,Medicine (miscellaneous) ,Zoology ,Biology ,digestive system ,Biochemistry ,Food Science - Abstract
BACKGROUND: Age-related alterations in the composition and function of gut microbiota may influence human health and disease mechanisms. However, connections between compositional changes in gut bacterial and fungal communities, and their role in the aging process, remain poorly understood. OBJECTIVE: Compare the gut microbiota and mycobiota composition in different age groups and evaluate the functionality. METHODS: In this study, we performed 16S rRNA and ITS2 gene-based microbial profiling analysis and shotgun metagenomics using the NextSeq platform. RESULTS: We observed a shift in compositional changes of human gut microbiota with age. Older individuals revealed a significantly different gut microbiota profile compared to younger individuals. For example, gut microbiota composition of the older individuals showed increase in genera Bacteroides, Blautia, Ruminococcaceae, and Escherichia coli. Additionally, older individuals had significant reduction in fungi belonging to saccharomyces cerevisiae and candida albicans in comparison to their younger counterparts. Moreover, metagenomics functional profiling analysis using shotgun metagenomics sequencing data showed substantial differences in the enrichment of 48 pathways between the young and older age groups. Metabolic pathways such as amino acid biosynthesis, carbohydrate metabolism, cell structure biosynthesis and vitamin biosynthesis were declined in the older age group, in comparison with the younger individuals. CONCLUSIONS: The identified differences provide a new insight to enrich our understanding of age-related changes in gut microbiota, their metabolic capabilities, and potential impact on health and disease conditions.
- Published
- 2022
16. Novel Derivatives of 4,6‐Dihydroxy‐2‐Quinolone‐3‐Carboxamides as Potential PI3Kα Inhibitors
- Author
-
Kamal Sweidan, Hussein Elfadel, Dima A. Sabbah, Sanaa K. Bardaweel, Rima Hajjo, Shabana Anjum, Jithna Sinoj, Vidhya A. Nair, Eman Abu‐Gharbieh, and Waseem El‐Huneidi
- Subjects
General Chemistry - Published
- 2022
17. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)
- Author
-
Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, and Haizhen A. Zhong
- Subjects
Combination therapy ,Antineoplastic Agents ,01 natural sciences ,Patents as Topic ,Phosphatidylinositol 3-Kinases ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Development ,Neoplasms ,Drug Discovery ,medicine ,Animals ,Humans ,Phosphatidylinositol ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Phosphoinositide-3 Kinase Inhibitors ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Kinase ,Cell growth ,business.industry ,Cancer ,General Medicine ,medicine.disease ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,chemistry ,Drug Resistance, Neoplasm ,Drug Design ,Mutation ,Cancer research ,Signal transduction ,business - Abstract
Introduction: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a central role in regulating cell growth and proliferation and...
- Published
- 2021
18. New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation
- Author
-
Kamal Sweidan, Ghassan Abu Sheikha, Sawsan Shraim, Bara’a A. Al-Azaideh, Wamidh H. Talib, Rima Hajjo, Aya M. Al-Zuheiri, and Dima A. Sabbah
- Subjects
Pharmacology ,0303 health sciences ,Chemistry ,pi3kα-inhibitors ,cheminformatics ,Pharmaceutical Science ,General Medicine ,Combinatorial chemistry ,03 medical and health sciences ,0302 clinical medicine ,Docking (dog) ,Design synthesis ,Cheminformatics ,030220 oncology & carcinogenesis ,docking ,hct-116 ,HD9665-9675 ,sulfonylhydrazones ,Pharmaceutical industry ,antitumor ,030304 developmental biology - Abstract
Phosphoinositide 3-kinase α (PI3Kα) is a propitious target for designing anticancer drugs. A series of new N’-(diphenylmethylene)benzenesulfonohydrazide was synthesized and characterized using FT-IR, NMR (1H and 13C), HRMS, and elemental analysis. Target compounds exhibited an antiproliferative effect against the human colon carcinoma (HCT-116) cell line. Our cheminformatics analysis indicated that the para-tailored derivatives [p-NO2 (3) and p-CF3 (7)] have better ionization potentials based on calculated Moran autocorrelations and ionization potentials. Subsequent in vitro cell proliferation assays validated our cheminformatics results by providing experimental evidence that both derivatives 3 and 7 exhibited improved antiproliferative activities against HCT-116. Hence, our results emphasized the importance of electron-withdrawing groups and hydrogen bond-acceptors in the rational design of small-molecule chemical ligands targeting PI3Kα. These results agreed with the induced-fit docking against PI3Kα, highlighting the role of p-substituted aromatic rings in guiding the ligand-PI3Kα complex formation, by targeting a hydrophobic pocket in the ligand-binding site and forming π-stacking interactions with a nearby tryptophan residue.
- Published
- 2021
19. An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors
- Author
-
Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, and Haizhen A. Zhong
- Subjects
Protease ,Middle East respiratory syndrome coronavirus ,viruses ,Viral pathogenesis ,medicine.medical_treatment ,virus diseases ,Host tropism ,General Medicine ,Biology ,medicine.disease_cause ,01 natural sciences ,Virology ,Virus ,respiratory tract diseases ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Viral replication ,Infectious disease (medical specialty) ,Drug Discovery ,medicine ,Coronavirus - Abstract
Coronaviruses (CoVs) are enveloped positive-stranded RNA viruses with spike (S) protein projections that allow the virus to enter and infect host cells. The S protein is a key virulence factor determining viral pathogenesis, host tropism, and disease pathogenesis. There are currently diverse corona viruses that are known to cause disease in humans. : The occurrence of Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), as fatal human CoV diseases, has induced significant interest in the medical field. The novel coronavirus disease (COVID-19) is an infectious disease caused by a novel strain of coronavirus (SAR-CoV-2). The SARS-CoV2 outbreak has been evolved in Wuhan, China, in December 2019, and identified as a pandemic in March 2020, resulting in 53.24 M cases and 1.20M deaths worldwide. : SARS-CoV-2 main proteinase (MPro), a key protease of CoV-2, mediates viral replication and transcription. SARS-CoV-2 MPro has been emerged as an attractive target for SARS-CoV-2 drug design and development. Diverse scaffolds have been released targeting SARS-CoV-2 MPro. In this review, we culminate the latest published information about SARS-CoV-2 main proteinase (MPro) and reported inhibitors.
- Published
- 2021
20. Design, Synthesis, and Biological Examination of N‐ Phenyl‐6‐fluoro‐4‐hydroxy‐2‐quinolone‐3‐carboxamides as Anticancer Agents
- Author
-
Dima A. Sabbah, Hla H. Samarat, Eveen Al‐Shalabi, Sanaa K. Bardaweel, Rima Hajjo, Kamal Sweidan, Reema Abu Khalaf, Aya M. Al‐Zuheiri, and Ghassan Abushaikha
- Subjects
General Chemistry - Published
- 2022
21. Sitagliptin: a potential drug for the treatment of COVID-19?
- Author
-
Rima Hajjo, Sanaa K. Bardaweel, and A. Dima A. Sabbah
- Subjects
SARS-CoV-2 ,COVID-19 ,DPP4 ,ACE2 ,sitagliptin ,drug repurposing ,XCL10 ,Viral pathogenesis ,Pharmaceutical Science ,Disease ,Crystallography, X-Ray ,medicine.disease_cause ,Bioinformatics ,Drug Delivery Systems ,0302 clinical medicine ,Data Mining ,dpp4 ,Gene Regulatory Networks ,Pharmaceutical industry ,Coronavirus ,media_common ,0303 health sciences ,Molecular Structure ,General Medicine ,sars-cov-2 ,Drug repositioning ,covid-19 ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,Sitagliptin ,HD9665-9675 ,Coronavirus Infections ,medicine.drug ,Drug ,Dipeptidyl Peptidase 4 ,media_common.quotation_subject ,Pneumonia, Viral ,Diabetes Complications ,03 medical and health sciences ,Viral entry ,cxcl10 ,medicine ,Humans ,Pandemics ,030304 developmental biology ,Pharmacology ,Dipeptidyl-Peptidase IV Inhibitors ,Integrative bioinformatics ,business.industry ,Sitagliptin Phosphate ,Drug Repositioning ,ace2 ,Computational Biology ,business - Abstract
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.
- Published
- 2020
22. The Epidemiology of Hundreds of Individuals Infected with Omicron BA.1 in Middle-Eastern Jordan
- Author
-
Rima Hajjo, Mahmoud M. AbuAlSamen, Hamed M. Alzoubi, and Raeda Alqutob
- Abstract
In less than two months of its detection in Jordan, lineage B.1.1.529 recognized as Omicron, is constituting 55% of all confirmed coronavirus disease of 2019 (COVID-19) infections causing a rise in the daily cases in the country. Herein, we report on 500 cases, among the first identified Omicron infections in Jordan. We also report on the genomic diversity of 25 Omicron viruses identified in nasopharyngeal swabs from Jordan. Our results indicated that 96% of study participants were vaccinated who had asymptomatic, mild or moderate disease. One unvaccinated individual developed severe disease. The median age of Omicron cases was 30 years, and most frequent disease symptoms were: fever, coughing, sore throat, runny nose, general fatigue and muscle/joint pain. Viral genomic analysis results revealed that the BA.1 is the dominant Omicron sublineage in Jordan, with 45 to 58 total mutations. We identified a few amino acid modifications that could impact the accuracy of some polymerase chain reaction (PCR) tests. In summary, infections caused by BA.1 seem milder than earlier infections. However, it is unknown whether this change is due to alterations in the immunity landscape of the infected population or is the result of viral genetic mutations that reduced viral virulence. Hence, comparing similar studies from different countries is likely to give us a get a better understanding of this variant, its behavior and the impact on disease characteristics.
- Published
- 2022
23. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML)
- Author
-
Alexander Tropsha, Sanaa K. Bardaweel, Dima A. Sabbah, and Rima Hajjo
- Subjects
Medicine (General) ,Clinical Biochemistry ,Tumor specific ,Review ,Machine learning ,computer.software_genre ,Imaging data ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,R5-920 ,medicine ,medicine.diagnostic_test ,business.industry ,Cancer ,biomarkers ,imaging ,Magnetic resonance imaging ,medicine.disease ,Biological materials ,Treatment efficacy ,machine learning ,030220 oncology & carcinogenesis ,oncology ,Identification (biology) ,Cancer biomarkers ,Artificial intelligence ,business ,computer ,MRI - Abstract
The identification of reliable and non-invasive oncology biomarkers remains a main priority in healthcare. There are only a few biomarkers that have been approved as diagnostic for cancer. The most frequently used cancer biomarkers are derived from either biological materials or imaging data. Most cancer biomarkers suffer from a lack of high specificity. However, the latest advancements in machine learning (ML) and artificial intelligence (AI) have enabled the identification of highly predictive, disease-specific biomarkers. Such biomarkers can be used to diagnose cancer patients, to predict cancer prognosis, or even to predict treatment efficacy. Herein, we provide a summary of the current status of developing and applying Magnetic resonance imaging (MRI) biomarkers in cancer care. We focus on all aspects of MRI biomarkers, starting from MRI data collection, preprocessing and machine learning methods, and ending with summarizing the types of existing biomarkers and their clinical applications in different cancer types.
- Published
- 2021
24. Emerging SARS-CoV-2 Lineages in Middle Eastern Jordan with Increasing Mutations Near Antibody Recognition Sites
- Author
-
Dima A. Sabbah, Rima Hajjo, and Sanaa K. Bardaweel
- Subjects
Transmission (mechanics) ,Middle East ,law ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,biology.protein ,Disease ,Biology ,Antibody ,Virology ,law.invention - Abstract
The genomic analysis of the 556 viral sequences from Jordan uncovered three dominant genetic SARS-CoV-2 lineages that are currently circulating in Jordan: B.1.1.312 (76%), B.1.36.10 (11%), and B.1.1.7 (6%), replacing the genetic strains that were dominant before sustained community transmission in Jordan. This raises speculations about these new genetic lineages and their relationship to the severity of disease symptoms in Jordan.
- Published
- 2021
25. New derivatives of sulfonylhydrazone as potential antitumor agents: Design, synthesis and cheminformatics evaluation
- Author
-
DIMA A. SABBAH, BARA’A A. AL-AZAIDEH, WAMIDH H. TALIB, RIMA HAJJO, KAMAL SWEIDAN, AYA M. AL-ZUHEIRI, GHASSAN ABU SHEIKHA, and SAWSAN SHRAIM
- Subjects
sulfonylhydrazones ,antitumor ,HCT-116 ,PI3Kα-inhibitors ,cheminformatics ,docking - Abstract
Phosphoinositide 3-kinase α (PI3Kα) is a propitious target for designing anticancer drugs. A series of new N'-(diphenylmethylene)benzenesulfonohydrazide was synthesized and characterized using FT-IR, NMR (1H and 13C), HRMS, and elemental analysis. Target compounds exhibited an antiproliferative effect against the human colon carcinoma (HCT-116) cell line. Our cheminformatics analysis indicated that the para-tailored derivatives [p-NO2 (3) and p-CF3 (7)] have better ionization potentials based on calculated Moran autocorrelations and ionization potentials. Subsequent in vitro cell proliferation assays validated our cheminformatics results by providing experimental evidence that both derivatives 3 and 7 exhibited improved antiproliferative activities against HCT-116. Hence, our results emphasized the importance of electron-withdrawing groups and hydrogen bond-acceptors in the rational design of small-molecule chemical ligands targeting PI3Kα. These results agreed with the induced-fit docking against PI3Kα, highlighting the role of p-substituted aromatic rings in guiding the ligand-PI3Kα complex formation, by targeting a hydrophobic pocket in the ligand-binding site and forming π-stacking interactions with a nearby tryptophan residue.
- Published
- 2021
26. The Influence of Coronavirus Diseases 2019 (COVID-19) Pandemic and the Quarantine Practices on University Students' Beliefs About the Online Learning Experience in Jordan
- Author
-
Fatin Atrooz, Abbas M. Almomany, Ahmad Qablan, Rima Hajjo, Ensaf Y. Almomani, and Huda Y. Almomani
- Subjects
Adult ,Male ,050103 clinical psychology ,knowledge ,Adolescent ,Distance education ,online learning ,Context (language use) ,Affect (psychology) ,law.invention ,Education, Distance ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,law ,Surveys and Questionnaires ,Quarantine ,Pandemic ,medicine ,Humans ,0501 psychology and cognitive sciences ,030212 general & internal medicine ,university students ,Students ,Pandemics ,Original Research ,Government ,Medical education ,Jordan ,SARS-CoV-2 ,pandemic ,lcsh:Public aspects of medicine ,05 social sciences ,Public Health, Environmental and Occupational Health ,quarantine ,COVID-19 ,lcsh:RA1-1270 ,medicine.disease ,Contagious disease ,Socioeconomic Factors ,distance learning ,Female ,Public Health ,Basic needs ,Psychology - Abstract
Coronavirus Disease 2019 (COVID-19) is a contagious disease that affects the respiratory system. In addition to the severe effects of the disease on health, the pandemic caused a negative impact on basic needs and services, employment, education, and economy worldwide. In Jordan, the whole country locked down, and quarantine was enforced by the military forces, which successfully controlled the spread of the disease. This research aims to study the influence of the COVID-19 pandemic and its associated quarantine on university students' beliefs about online learning practice in Jordan. An online descriptive survey involved questions that covered students' demographic information, student's basic and advanced knowledge about COVID-19, students' online learning experience during the quarantine, and finally students' views on the enforced quarantine practice in Jordan. Results showed that students have a good knowledge (>50%) about the COVID-19 basic information and a moderate knowledge (90%) supported the military-enforced quarantine implemented in the country despite the hard time the students had during the quarantine. We conclude that university students were able to protect themselves from COVID-19 through their good knowledge about the infectious disease and their commitment to follow the rules imposed by the Government of Jordan. Nevertheless, the challenges caused by the pandemic and its associated quarantine, combined with the sudden unprecedented online experience, negatively impacted students' thoughts and beliefs about the online learning experience during the quarantine. Further studies need to be performed in this context. We hope our results will help decision-makers better understand the students' attitudes and motivation toward online learning and how this will affect their future plans and decisions.
- Published
- 2021
27. Sitagliptin: a potential drug for the treatment of COVID-19?
- Author
-
SANAA K. BARDAWEEL, RIMA HAJJO, A. DIMA A. SABBAH, SANAA K. BARDAWEEL, RIMA HAJJO, and A. DIMA A. SABBAH
- Abstract
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.
- Published
- 2021
28. N-Phenyl-6-Chloro-4-Hydroxy-2-Quinolone-3-CarboxAmides: Molecular Docking, Synthesis, and Biological Investigation as Anticancer Agents
- Author
-
Rawan A. Haroon, Dima A. Sabbah, Sanaa K. Bardaweel, Kamal Sweidan, and Rima Hajjo
- Subjects
PI3Kα ,Colorectal cancer ,Stereochemistry ,Pharmaceutical Science ,medicine.disease_cause ,anticancer ,01 natural sciences ,Article ,Analytical Chemistry ,lcsh:QD241-441 ,03 medical and health sciences ,chemistry.chemical_compound ,lcsh:Organic chemistry ,Drug Discovery ,medicine ,Phosphatidylinositol ,Physical and Theoretical Chemistry ,Binding site ,Protein kinase B ,IC50 ,030304 developmental biology ,0303 health sciences ,010405 organic chemistry ,Chemistry ,AKT ,Organic Chemistry ,medicine.disease ,0104 chemical sciences ,quinolone-3-carboxamide ,colon cancer ,Chemistry (miscellaneous) ,Docking (molecular) ,Cell culture ,docking ,Molecular Medicine ,Carcinogenesis ,human activities - Abstract
Cancer is a multifactorial disease and the second leading cause of death worldwide. Diverse factors induce carcinogenesis, such as diet, smoking, radiation, and genetic defects. The phosphatidylinositol 3-kinase (PI3K&alpha, ) has emerged as an attractive target for anticancer drug design. Eighteen derivatives of N-phenyl-6-chloro-4-hydroxy-2-quinolone-3-carboxamide were synthesized and characterized using FT-IR, NMR (1H and 13C), and high-resolution mass spectra (HRMS). The series exhibited distinct antiproliferative activity (IC50 µ, M) against human epithelial colorectal adenocarcinoma (Caco-2) and colon carcinoma (HCT-116) cell lines, respectively: compounds 16 (37.4, 8.9 µ, M), 18 (50.9, 3.3 µ, M), 19 (17.0, 5.3 µ, M), and 21 (18.9, 4.9 µ, M). The induced-fit docking (IFD) studies against PI3K&alpha, s showed that the derivatives occupy the PI3K&alpha, binding site and engage with key binding residues.
- Published
- 2020
- Full Text
- View/download PDF
29. Chemocentric Informatics Analysis: Dexamethasone Versus Combination Therapy for COVID-19
- Author
-
Dima A. Sabbah, Rima Hajjo, and Sanaa K. Bardaweel
- Subjects
Drug ,Combination therapy ,business.industry ,media_common.quotation_subject ,General Chemical Engineering ,General Chemistry ,Pharmacology ,Article ,Chemistry ,Pharmacotherapy ,Informatics ,Medicine ,Formoterol ,Salmeterol ,business ,QD1-999 ,Dexamethasone ,medicine.drug ,media_common ,Treprostinil - Abstract
COVID-19 is a biphasic infectious disease with no approved vaccine or pharmacotherapy. The first drug that has shown promise in reducing COVID-19 mortality in severely-ill patients is dexamethasone, a cheap, well-known anti-inflammatory glucocorticoid, approved for the treatment of inflammatory conditions including respiratory diseases such as asthma and tuberculosis. However, about 80% of COVID-19 patients requiring oxygenation, and about 67% of patients on ventilators, are not responsive to dexamethasone therapy mainly. Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure. In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of the drug, we applied a chemocentric informatics approach to identify combination therapies. Our results indicated that combining dexamethasone with fast long-acting beta-2 adrenergic agonists (LABAs), such as formoterol and salmeterol, can ease respiratory symptoms hastily, until dexamethasone's anti-inflammatory and immunosuppressant effects kick in. Our studies demonstrated that LABAs and dexamethasone (or other glucocorticoids) exert synergistic effects that will augment both anti-inflammatory and fibronectin-mediated anticoagulant effects. We also propose other alternatives to LABAs that are supported by sound systems biology evidence, such as nitric oxide. Other drugs such as sevoflurane and treprostinil interact with the SARS-CoV-2 interactome and deserve further exploration. Moreover, our chemocentric informatics approach provides systems biology evidence that combination therapies for COVID-19 will have higher chances of perturbing the SARS-CoV-2 human interactome, which may negatively impact COVID-19 disease pathways.
- Published
- 2020
- Full Text
- View/download PDF
30. An Updated Review on SARS-CoV-2 Main Proteinase (M
- Author
-
Dima A, Sabbah, Rima, Hajjo, Sanaa K, Bardaweel, and Haizhen A, Zhong
- Subjects
SARS-CoV-2 ,Phytochemicals ,Gene Expression ,Antiviral Agents ,Protein Structure, Secondary ,High-Throughput Screening Assays ,COVID-19 Drug Treatment ,Molecular Docking Simulation ,Structure-Activity Relationship ,Catalytic Domain ,Drug Discovery ,Humans ,Protease Inhibitors ,Protein Interaction Domains and Motifs ,Amino Acid Sequence ,Coronavirus 3C Proteases ,Protein Binding - Abstract
[Coronaviruses (CoVs) are enveloped positive-stranded RNA viruses with spike (S) protein projections that allow the virus to enter and infect host cells. The S protein is a key virulence factor determining viral pathogenesis, host tropism, and disease pathogenesis. There are currently diverse corona viruses that are known to cause disease in humans. The occurrence of Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), as fatal human CoV diseases, has induced significant interest in the medical field. The novel coronavirus disease (COVID-19) is an infectious disease caused by a novel strain of coronavirus (SAR-CoV-2). The SARS-CoV2 outbreak has been evolved in Wuhan, China, in December 2019, and identified as a pandemic in March 2020, resulting in 53.24 M cases and 1.20M deaths worldwide. SARS-CoV-2 main proteinase (M
- Published
- 2020
31. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery
- Author
-
Rima Hajjo, Haizhen A. Zhong, Dima A. Sabbah, and Sanaa K. Bardaweel
- Subjects
viruses ,Cathepsin L ,Phytochemicals ,Host tropism ,Gene Expression ,Plasma protein binding ,medicine.disease_cause ,Antiviral Agents ,Virus ,Small Molecule Libraries ,Structure-Activity Relationship ,Viral entry ,Drug Discovery ,Pandemic ,medicine ,Humans ,Protease Inhibitors ,Coronavirus ,Plants, Medicinal ,biology ,Drug discovery ,SARS-CoV-2 ,Serine Endopeptidases ,virus diseases ,COVID-19 ,General Medicine ,Virus Internalization ,biology.organism_classification ,Virology ,COVID-19 Drug Treatment ,Spike Glycoprotein, Coronavirus ,Receptors, Virus ,Angiotensin-Converting Enzyme 2 ,Betacoronavirus ,Protein Binding - Abstract
Even after one year of its first outbreak reported in China, the coronavirus disease 2019 (COVID-19) pandemic is still sweeping the World, causing serious infections and claiming more fatalities. COVID-19 is caused by the novel coronavirus SARS-CoV-2, which belongs to the genus Betacoronavirus (β-CoVs), which is of greatest clinical importance since it contains many other viruses that cause respiratory disease in humans, including OC43, HKU1, SARS-CoV, and MERS. The spike (S) glycoprotein of β-CoVs is a key virulence factor in determining disease pathogenesis and host tropism, and it also mediates virus binding to the host’s receptors to allow viral entry into host cells, i.e., the first step in virus lifecycle. Viral entry inhibitors are considered promising putative drugs for COVID-19. Herein, we mined the biomedical literature for viral entry inhibitors of other coronaviruses, with special emphasis on β-CoVs entry inhibitors. We also outlined the structural features of SARS-CoV-2 S protein and how it differs from other β-CoVs to better understand the structural determinants of S protein binding to its human receptor (ACE2). This review highlighted several promising viral entry inhibitors as potential treatments for COVID-19.
- Published
- 2020
32. A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-molecule BCG Mimics to Prevent COVID-19 Mortality
- Author
-
Rima Hajjo and Alexander Tropsha
- Subjects
Drug ,Innate immune system ,business.industry ,media_common.quotation_subject ,Systems biology ,medicine.disease_cause ,Herd immunity ,Immune system ,Immunity ,Immunology ,Medicine ,Viral disease ,business ,media_common ,Coronavirus - Abstract
Background. Coronavirus disease 2019 (COVID-19) is expected to continue to cause worldwide fatalities until the World population develops ‘herd immunity’, or until a vaccine is developed and used as a prevention. However, the vaccine may prove ineffective due to rapid changes in viral antigenic determinants. Bacillus Calmette–Guerin (BCG) vaccine has been recognized for its beneficial effects on the immune system, and it is currently in being tested in clinical trials for COVID-19. However, BCG shortages may affect clinical decisions regarding the prioritization of BCG to protect from viral infections, hence, small-molecule BCG-mimics will be valuable alternatives. Methods. We developed and applied a systems biology workflow capable of identifying antiviral drugs and vaccines that can boast immunity and impact viral disease pathways to prevent the fatal consequences of COVID-19. Results. Our results indicate that BCG and small-molecule BCG-mimics affect the production and maturation of naive T cells, which results in enhanced long-lasting innate immune responses to tackle novel viruses. Our workflow identified several antiviral drugs including raltegravir and lopinavir as high confidence BCG mimics. Top hits including emetine and lopinavir were validated to inhibit the growth of novel coronavirus SARS-CoV-2 in vitro. Conclusions. Herein, we provide systems biology support for using BCG as a protection measure from the lethal consequences of emergent viruses including SARS-CoV-2. We also provide systems biology evidence that certain small molecule drugs could mimic the effects of BCG and serve as alternatives to BCG.
- Published
- 2020
33. A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-molecule BCG Mimics to Protect from COVID-19
- Author
-
Rima Hajjo and Alexander Tropsha
- Subjects
Innate immune system ,Immune system ,business.industry ,Immunity ,Systems biology ,Immunology ,Medicine ,Viral disease ,business ,medicine.disease_cause ,Repurposing ,Herd immunity ,Coronavirus - Abstract
Background. Coronavirus disease 2019 (COVID-19) is expected to continue to cause worldwide fatalities until the World population develops ‘herd immunity’, or until a vaccine is developed and used as a prevention. However, the vaccine may prove ineffective due to rapid changes in viral antigenic determinants. Bacillus Calmette–Guerin (BCG) vaccine has been recognized for its beneficial effects on the immune system, and it is currently in being tested in clinical trials for COVID-19. However, BCG shortages may affect clinical decisions regarding the prioritization of BCG to protect from viral infections, hence, small-molecule BCG-mimics will be valuable alternatives. Methods. We developed and applied a systems biology workflow capable of identifying antiviral drugs and vaccines that can boast immunity and impact viral disease pathways to prevent the fatal consequences of COVID-19. Results. Our results indicate that BCG and small-molecule BCG-mimics affect the production and maturation of naive T cells, which results in enhanced long-lasting innate immune responses to tackle novel viruses. Our workflow identified several antiviral drugs including raltegravir and lopinavir as high confidence BCG mimics. Top hits including emetine and lopinavir were validated to inhibit the growth of novel coronavirus SARS-CoV-2 in vitro. Conclusions. Herein, we provide systems biology support for using BCG as a protection measure from the lethal consequences of emergent viruses including SARS-CoV-2. We also provide systems biology evidence that certain small molecule drugs could mimic the effects of BCG and serve as alternatives to BCG.
- Published
- 2020
34. An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
- Author
-
Kamal Sweidan, Haizhen A. Zhong, Dima A. Sabbah, and Rima Hajjo
- Subjects
ABL ,Informatics ,Chemistry ,In silico ,breakpoint cluster region ,Fusion Proteins, bcr-abl ,Antineoplastic Agents ,General Medicine ,Computational biology ,medicine.disease ,Molecular Docking Simulation ,Mechanism of action ,Cheminformatics ,Docking (molecular) ,Drug Discovery ,medicine ,Molecular Medicine ,Humans ,medicine.symptom ,Protein Kinase Inhibitors ,Chronic myelogenous leukemia ,K562 cells - Abstract
Background: Drugs incorporating heterocyclic chemical skeletons possess a plethora of therapeutic activities such as anticancer, antimicrobial, antihypertensive, and antipsychiatric effects. It is becoming routine, nowadays, to use cheminformatics and bioinformatics methods to elucidate the mechanism(s) of action of such drugs. Objective: To probe the activity of a recently published series of N1-(anthraquinon-2-yl) amidrazone piperazine derivatives employing computational strategies[1], identify their structural basis of binding to BCR/ABL kinase domain, and explain their anticancer activities in human breast adenocarcinoma (MCF-7) and chronic myelogenous leukemia (K562) cell lines. Methods: We applied an in silico integrative informatics approach integrating molecular descriptors, docking studies, cheminformatics, and network analysis. Results: Our results highlighted the possible involvement of the BCR/ABL and DRD2 pathways in the anticancer activity of the studied compounds, and induced fit docking (IFD) indicated that the BCR/ABL kinase domain is a putative drug target. Additionally, high-scoring docking poses identified a unique network of hydrogen bonding with amino acids Y253, K271, E286, V299, L301, T315, M318, I360, R362, V379, and D3810. Conclusion: Using an integrative informatics approach to characterize our anticancer compounds, we were able to explain the biological differences between synthesized and biologically validated amidrazone piperazine anticancer agents. We were also able to postulate a mechanism of action of this novel group of anticancer agents.
- Published
- 2020
35. Salivary Microbiome and Cigarette Smoking: A First of Its Kind Investigation in Jordan
- Author
-
Rima Hajjo, Ahmed Abu-Siniyeh, Sarah Hajjaj, and Walid Al-Zyoud
- Subjects
Male ,Saliva ,Health, Toxicology and Mutagenesis ,Population ,lcsh:Medicine ,microbiome ,Article ,smoking ,Cigarette Smoking ,03 medical and health sciences ,0302 clinical medicine ,Metabolomics ,Cigarette smoking ,RNA, Ribosomal, 16S ,Prevotella ,Humans ,operational taxonomic unit (OTU) ,Microbiome ,16S rRNA ,education ,030304 developmental biology ,0303 health sciences ,education.field_of_study ,saliva ,Jordan ,biology ,Bacteria ,Microbiota ,lcsh:R ,Public Health, Environmental and Occupational Health ,bioinformatics ,biology.organism_classification ,Hypervariable region ,stomatognathic diseases ,RNA, Bacterial ,030220 oncology & carcinogenesis ,Immunology ,next-generation sequencing ,Neisseria - Abstract
There is accumulating evidence in the biomedical literature suggesting the role of smoking in increasing the risk of oral diseases including some oral cancers. Smoking alters microbial attributes of the oral cavity by decreasing the commensal microbial population and increasing the pathogenic microbes. This study aims to investigate the shift in the salivary microbiota between smokers and non-smokers in Jordan. Our methods relied on high-throughput next-generation sequencing (NGS) experiments for V3-V4 hypervariable regions of the 16S rRNA gene, followed by comprehensive bioinformatics analysis including advanced multidimensional data visualization methods and statistical analysis approaches. Six genera&mdash, Streptococcus, Prevotella, Vellionella, Rothia, Neisseria, and Haemophilus&mdash, predominated the salivary microbiota of all samples with different percentages suggesting the possibility for the salivary microbiome to restored after quitting smoking. Three genera&mdash, Streptococcus, Prevotella, and Veillonella&mdash, showed significantly elevated levels among smokers at the expense of Neisseria in non-smokers. In conclusion, smoking has a definite impact on shifting the salivary microbiota in smokers. We can suggest that there is microbial signature at the genera level that can be used to classify smokers and non-smokers by Linear Discriminant Analysis Effect Size (LEfSe) based on the salivary abundance of genera. Proteomics and metabolomics studies are highly recommended to fully understand the effect of bacterial endotoxin release and xenobiotic metabolism on the bacterial interrelationships in the salivary microbiome and how they affect the growth of each other in the saliva of smokers.
- Published
- 2019
36. Multiresidue pesticide analysis of the medicinal plantOriganum syriacum
- Author
-
Rima Hajjo, Abdelkader Battah, and Fatma U. Afifi
- Subjects
Chromatography, Gas ,Plants, Medicinal ,Chromatography ,Pesticide residue ,biology ,Health, Toxicology and Mutagenesis ,Beverage industry ,Pesticide Residues ,Public Health, Environmental and Occupational Health ,General Chemistry ,Origanum ,Pesticide ,Toxicology ,biology.organism_classification ,chemistry.chemical_compound ,chemistry ,Magnesium Silicates ,Chemistry (miscellaneous) ,Origanum syriacum ,Petroleum ether ,Dicofol ,Vinclozolin ,Food Science - Abstract
Origanum syriacum is a medicinal plant widely used in Jordan both as a folk remedy and in the food and beverage industry. As the plant can be treated with pesticides during commercial production, three different methods for pesticide multiresidue analysis of this plant have been evaluated. One method based on soxhlet extraction followed by acetonitrile/petroleum ether (PE) partitioning was found to be particularly suitable. Extracts were cleaned-up using a Florisil column. Mean recoveries of pesticides from spiked herbal samples were 74-119%, with coefficients of variation between 1.0 and 23.6%. The limits of detection were in the range 0.0008-0.5 mg kg(-1). The method was used for the determination of pesticide residues in O. syriacum samples purchased from the local market. Seven out of eight samples contained detectable levels of dichlorodiphenyltrichloroethane (DDT), folpet, dicofol, hexachlorobenzene (HCB), hecachlorocyclohexane (HCH), quintozene, transchlordane and vinclozolin.
- Published
- 2007
37. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers
- Author
-
Bryan L. Roth, Vincent Setola, Alexander Tropsha, and Rima Hajjo
- Subjects
Selective Estrogen Receptor Modulators ,Quantitative structure–activity relationship ,Informatics ,Drug Evaluation, Preclinical ,Quantitative Structure-Activity Relationship ,Computational biology ,Biology ,Bioinformatics ,Ligands ,Article ,chemistry.chemical_compound ,User-Computer Interface ,Cognition ,Alzheimer Disease ,Cell Line, Tumor ,Drug Discovery ,Chemogenomics ,Humans ,Cloning, Molecular ,Receptor ,Enhancer ,Nootropic Agents ,Virtual screening ,Drug discovery ,Reproducibility of Results ,Genomics ,chemistry ,Selective estrogen receptor modulator ,Raloxifene Hydrochloride ,Receptors, Serotonin ,Molecular Medicine ,Serotonin Antagonists - Abstract
We have devised a chemocentric informatics methodology for drug discovery integrating independent approaches to mining biomolecular databases. As a proof of concept, we have searched for novel putative cognition enhancers. First, we generated Quantitative Structure-Activity Relationship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor (5-HT(6)R), a known target for cognition enhancers, and employed these models for virtual screening to identify putative 5-HT(6)R actives. Second, we queried chemogenomics data from the Connectivity Map ( http://www.broad.mit.edu/cmap/ ) with the gene expression profile signatures of Alzheimer's disease patients to identify compounds putatively linked to the disease. Thirteen common hits were tested in 5-HT(6)R radioligand binding assays and ten were confirmed as actives. Four of them were known selective estrogen receptor modulators that were never reported as 5-HT(6)R ligands. Furthermore, nine of the confirmed actives were reported elsewhere to have memory-enhancing effects. The approaches discussed herein can be used broadly to identify novel drug-target-disease associations.
- Published
- 2012
38. Development, Validation, and Use of Quantitative Structure−Activity Relationship Models of 5-Hydroxytryptamine (2B) Receptor Ligands to Identify Novel Receptor Binders and Putative Valvulopathic Compounds among Common Drugs
- Author
-
Rima Hajjo, Christopher M. Grulke, Alexander Golbraikh, Vincent Setola, Xi Ping Huang, Alexander Tropsha, and Bryan L. Roth
- Subjects
Models, Molecular ,Drug ,Agonist ,Quantitative structure–activity relationship ,Databases, Factual ,Drug-Related Side Effects and Adverse Reactions ,medicine.drug_class ,In silico ,media_common.quotation_subject ,Heart Valve Diseases ,Quantitative Structure-Activity Relationship ,Pharmacology ,Ligands ,Binding, Competitive ,Article ,Radioligand Assay ,Dexfenfluramine ,Fenfluramine ,Receptor, Serotonin, 5-HT2B ,Drug Discovery ,medicine ,Receptor ,media_common ,Chemistry ,5-HT2B receptor ,Pharmaceutical Preparations ,Radioligand binding ,Molecular Medicine ,Algorithms ,Serotonin 5-HT2 Receptor Agonists - Abstract
Some antipsychotic drugs are known to cause valvular heart disease by activating serotonin 5-HT(2B) receptors. We have developed and validated binary classification QSAR models capable of predicting potential 5-HT(2B) actives. The classification accuracies of the models built to discriminate 5-HT(2B) actives from the inactives were as high as 80% for the external test set. These models were used to screen in silico 59,000 compounds included in the World Drug Index, and 122 compounds were predicted as actives with high confidence. Ten of them were tested in radioligand binding assays and nine were found active, suggesting a success rate of 90%. All validated actives were then tested in functional assays, and one compound was identified as a true 5-HT(2B) agonist. We suggest that the QSAR models developed in this study could be used as reliable predictors to flag drug candidates that are likely to cause valvulopathy.
- Published
- 2010
- Full Text
- View/download PDF
39. Medicinal Plants, Pesticide Residues, and Analysis
- Author
-
Abdelkader Battah, Rima Hajjo, and Fatma A
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.